Serious adverse events by week 8 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in serious adverse events by week 8 compared with placebo (low certainty).
1 finding from 1 review
Adverse events and complications · women undergoing outpatient hysteroscopy
Saline probably leads to lower adverse events and complications compared with carbon dioxide (moderate certainty).
1 finding from 1 review
Adverse events and complications · women undergoing outpatient hysteroscopy
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with morphine (very low certainty).
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Nausea · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – nausea compared with oxycodone (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: any (Duration of · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in adverse events: any (Duration of (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serious or severe adverse events · people with diabetes and orthostatic hypotension
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Very low
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
It is very uncertain whether enteric‐release glyceryl trinitrate changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether low FODMAP diet changes withdrawal due to adverse events compared with sham diet (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · UC patients
It is very uncertain whether yoga intervention changes withdrawal due to adverse events compared with no intervention (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · UC patients
It is very uncertain whether low FODMAPs diet changes withdrawal due to adverse events compared with sham diet (very low certainty).
1 finding from 1 review
All‐cause serious adverse events · the promotion of growth and prevention of infections in infants less than six months of age
Efficacy and safety of a first dose of whole‐cell pertussis vaccine showed no clear difference in all‐cause serious adverse events compared with a first dose of acellular pertussis vaccine (moderate certainty).
1 finding from 1 review
Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low